Tumor acidity, chemoresistance and proton pump inhib

Future Oncology 1, 779-786 DOI: 10.2217/14796694.1.6.779

Citation Report

#	Article	IF	CITATIONS
1	Differential Expression of Novel Tyrosine Kinase Substrates during Breast Cancer Development. Molecular and Cellular Proteomics, 2007, 6, 2072-2087.	2.5	120
2	Proton Pump Inhibitors Induce Apoptosis of Human B-Cell Tumors through a Caspase-Independent Mechanism Involving Reactive Oxygen Species. Cancer Research, 2007, 67, 5408-5417.	0.4	280
3	Cannibalism: A way to feed on metastatic tumors. Cancer Letters, 2007, 258, 155-164.	3.2	132
4	Targeting Vacuolar H+-ATPases as a New Strategy against Cancer. Cancer Research, 2007, 67, 10627-10630.	0.4	247
5	Correlation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers. Journal of Surgical Oncology, 2007, 96, 220-229.	0.8	39
6	Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1178-1182.	1.4	180
7	Drug distribution in tumors: Mechanisms, role in drug resistance, and methods for modification. Current Oncology Reports, 2007, 9, 109-114.	1.8	73
8	Lysosomes in iron metabolism, ageing and apoptosis. Histochemistry and Cell Biology, 2008, 129, 389-406.	0.8	263
9	High-performance liquid chromatography enantioseparation of proton pump inhibitors using the immobilized amylose-based Chiralpak IA chiral stationary phase in normal-phase, polar organic and reversed-phase conditions. Journal of Chromatography A, 2008, 1177, 105-113.	1.8	71
10	Extracellular Acidification Elicits Spatially and Temporally Distinct Ca 2+ Signals. Current Biology, 2008, 18, 781-785.	1.8	72
11	pH-Responsive Nanoparticles for Cancer Drug Delivery. Methods in Molecular Biology, 2008, 437, 183-216.	0.4	61
12	Lysosomes and oxidative stress in aging and apoptosis. Biochimica Et Biophysica Acta - General Subjects, 2008, 1780, 1291-1303.	1.1	236
13	Tumor–Microenvironment Interactions: Dangerous Liaisons. Advances in Cancer Research, 2008, 100, 203-229.	1.9	113
14	Osmotic and Ionic Regulation in Insects. , 2008, , 231-293.		4
15	Increasing Expression of Monocarboxylate Transporters 1 and 4 Along Progression to Invasive Cervical Carcinoma. International Journal of Gynecological Pathology, 2008, 27, 568-574.	0.9	84
16	The Janusâ€faced role of ezrin in "linking―cells to either normal or metastatic phenotype. International Journal of Cancer, 2009, 125, 2239-2245.	2.3	52
17	Dextran–doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 415-425.	3.3	95
18	Vacuolar H ⁺ â€ATPase inhibitors overcome Bclâ€xLâ€mediated chemoresistance through restoration of a caspaseâ€independent apoptotic pathway. Cancer Science, 2009, 100, 1460-1467.	1.7	54

#	Article	IF	CITATIONS
19	Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biology International, 2009, 33, 1008-1019.	1.4	59
20	Chiral Separation of Tenatoprazole and Several Related Benzimidazoles by Normal Phase LC Using Amylose-Based Stationary Phase. Chromatographia, 2009, 70, 1039-1044.	0.7	4
21	V H+-ATPase along the yeast secretory pathway: Energization of the ER and Golgi membranes. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 303-313.	1.4	12
22	Role of V-ATPases in solid tumors: Importance of the subunit C (Review). International Journal of Oncology, 2009, 34, 1513-20.	1.4	47
23	Evaluation of endogenous acidic metabolic products associated with carbohydrate metabolism in tumor cells. Cell Biology and Toxicology, 2010, 26, 177-188.	2.4	36
24	Tumoral acidic pH-responsive MPEG-poly(\hat{l}^2 -amino ester) polymeric micelles for cancer targeting therapy. Journal of Controlled Release, 2010, 144, 259-266.	4.8	263
25	pHâ€dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. International Journal of Cancer, 2010, 127, 207-219.	2.3	237
26	Proton pump inhibitorâ€induced tumour cell death by inhibition of a detoxification mechanism. Journal of Internal Medicine, 2010, 267, 515-525.	2.7	92
27	Mitochondrial Turnover and Aging of Long-Lived Postmitotic Cells: The Mitochondrial–Lysosomal Axis Theory of Aging. Antioxidants and Redox Signaling, 2010, 12, 503-535.	2.5	401
29	Measurement of ATP6V1C1 expression in brush cytology samples as a diagnostic and prognostic marker in oral squamous cell carcinoma. Cancer Biology and Therapy, 2010, 9, 1057-1064.	1.5	45
30	Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death and Disease, 2010, 1, e87-e87.	2.7	155
31	Proton dynamics in cancer. Journal of Translational Medicine, 2010, 8, 57.	1.8	97
32	Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar ATPases. Cancer Letters, 2010, 295, 135-143.	3.2	74
33	Synthesis and Characterization of Lipid–Polymer Hybrid Nanoparticles with pH-Triggered Poly(ethylene glycol) Shedding. Langmuir, 2011, 27, 10556-10561.	1.6	80
34	Rapid dissolution of ZnO nanocrystals in acidic cancer microenvironment leading to preferential apoptosis. Nanoscale, 2011, 3, 3657.	2.8	118
35	Teaching New Dogs Old Tricks: Membrane Biophysical Properties in Drug Delivery and Resistance. Recent Patents on Anti-Cancer Drug Discovery, 2011, 6, 334-346.	0.8	3
36	Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein. Cancer Chemotherapy and Pharmacology, 2011, 68, 1179-1190.	1.1	32
37	Bicarbonate and dichloroacetate: Evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer, 2011, 11, 235.	1.1	54

#	Article	IF	CITATIONS
38	Stable and sensitive probes for lysosomes: Cellâ€penetrating fluorescent calix[4]arenes accumulate in acidic vesicles. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 126-136.	1.1	18
39	5â€Nitroâ€2â€(3â€Phenylpropylamino) Benzoic Acid Induced Drug Resistance to Cisplatin in Human Erythroleukemia Cell Lines. Anatomical Record, 2011, 294, 945-952.	0.8	18
40	The <i>a</i> 3 Isoform Vacuolar Type H+-ATPase Promotes Distant Metastasis in the Mouse B16 Melanoma Cells. Molecular Cancer Research, 2011, 9, 845-855.	1.5	131
41	Tumor Acidity as Evolutionary Spite. Cancers, 2011, 3, 408-414.	1.7	87
42	Autophagy Is a Protective Mechanism for Human Melanoma Cells under Acidic Stress. Journal of Biological Chemistry, 2012, 287, 30664-30676.	1.6	153
43	Expression and functional role of vacuolar H+-ATPase in human hepatocellular carcinoma. Carcinogenesis, 2012, 33, 2432-2440.	1.3	61
44	A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents. Current Pharmaceutical Design, 2012, 18, 1395-1406.	0.9	50
45	Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes. Current Pharmaceutical Design, 2012, 18, 1407-1413.	0.9	16
46	Genome-wide analysis of intracellular pH reveals quantitative control of cell division rate by pHc in Saccharomyces cerevisiae. Genome Biology, 2012, 13, R80.	13.9	139
47	Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH. Translational Oncology, 2012, 5, 208-216.	1.7	42
48	Self-Assembled Polymeric Nanomicelles as Delivery Carriers for Antitumor Drug Camptothecin. Journal of Dispersion Science and Technology, 2012, 33, 293-306.	1.3	4
49	Acidosis Promotes Bcl-2 Family-mediated Evasion of Apoptosis. Journal of Biological Chemistry, 2012, 287, 27863-27875.	1.6	60
50	Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 943-958.	1.5	29
51	Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by downâ€regulating the Vâ€ATPases/mTOR/HIFâ€1α/Pâ€gp and MRP1 signaling pathway in vitro and in vivo. Journa of Cellular Biochemistry, 2012, 113, 2474-2487.	1.2	76
52	Synthesis of pH and temperature sensitive, core–shell nano/microgels, by one pot, soap-free emulsion polymerization. Journal of Colloid and Interface Science, 2012, 369, 82-90.	5.0	43
53	Metabolic symbiosis in cancer: Refocusing the Warburg lens. Molecular Carcinogenesis, 2013, 52, 329-337.	1.3	131
54	Engineered Culture Models for Studies of Tumor-Microenvironment Interactions. Annual Review of Biomedical Engineering, 2013, 15, 29-53.	5.7	122
55	Production of Cyr61 protein is modulated by extracellular acidification and PI3K/Akt signaling in prostate carcinoma PC-3 cells. Food and Chemical Toxicology. 2013. 58. 169-176.	1.8	15

#	ARTICLE	IF	CITATIONS
56	Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs – an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research. Journal of Translational Medicine, 2013, 11, 282.	1.8	135
57	Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. Journal of Translational Medicine, 2013, 11, 268.	1.8	115
58	Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. Advanced Drug Delivery Reviews, 2013, 65, 1686-1698.	6.6	209
59	The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: The unique way of multi-drug resistance modulation. Experimental Cell Research, 2013, 319, 1013-1027.	1.2	31
60	Increased LDH5 expression is associated with lymph node metastasis and outcome in oral squamous cell carcinoma. Clinical and Experimental Metastasis, 2013, 30, 529-540.	1.7	27
61	Non-Hodgkin's B-cell lymphoma: Advances in molecular strategies targeting drug resistance. Experimental Biology and Medicine, 2013, 238, 971-990.	1.1	52
62	Functional imaging of the bowel. Abdominal Imaging, 2013, 38, 1203-1213.	2.0	2
63	Visualizing and Manipulating Focal Adhesion Kinase Regulation in Live Cells. Journal of Biological Chemistry, 2013, 288, 8875-8886.	1.6	34
64	Enantiomeric separation of proton pump inhibitors on new generation chiral columns using LC and supercritical fluid chromatography. Journal of Separation Science, 2013, 36, 3004-3010.	1.3	22
65	Blood oxygen levelâ€dependent liver MRI: Can It predict microvascular invasion in HCC?. Journal of Magnetic Resonance Imaging, 2013, 37, 692-699.	1.9	20
66	Hypoxia-regulated microRNAs in human cancer. Acta Pharmacologica Sinica, 2013, 34, 336-341.	2.8	128
67	Chemoresistance to Concanamycin A1 in Human Oral Squamous Cell Carcinoma Is Attenuated by an HDAC Inhibitor Partly via Suppression of Bcl-2 Expression. PLoS ONE, 2013, 8, e80998.	1.1	22
68	Cell volume regulation in epithelial physiology and cancer. Frontiers in Physiology, 2013, 4, 233.	1.3	81
69	Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine. Autophagy, 2014, 10, 562-571.	4.3	176
70	Extracellular Vesicles as Shuttles of Tumor Biomarkers and Anti-Tumor Drugs. Frontiers in Oncology, 2014, 4, 267.	1.3	85
71	Intratumoral Decorin Gene Delivery by AAV Vector Inhibits Brain Glioblastomas and Prolongs Survival of Animals by Inducing Cell Differentiation. International Journal of Molecular Sciences, 2014, 15, 4393-4414.	1.8	31
72	Why electroporation is a useful technique for cancer treatments. , 2014, , 103-125.		11
73	Normal and polarâ€organicâ€phase highâ€performance liquid chromatographic enantioresolution of omeprazole, rabeprazole, lansoprazole and pantoprazole using monochloroâ€methylated celluloseâ€based chiral stationary phase and determination of dexrabeprazole. Biomedical Chromatography. 2014. 28. 112-119.	0.8	13

#	Article	IF	CITATIONS
74	The Intercellular Metabolic Interplay between Tumor and Immune Cells. Frontiers in Immunology, 2014, 5, 358.	2.2	77
75	The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer. European Journal of Pharmaceutical Sciences, 2014, 51, 96-109.	1.9	49
76	Utilizing hydrogen sulfide as a novel anti ancer agent by targeting cancer glycolysis and p <scp>H</scp> imbalance. British Journal of Pharmacology, 2014, 171, 4322-4336.	2.7	118
77	Mitochondrial substrates in cancer: Drivers or passengers?. Mitochondrion, 2014, 19, 8-19.	1.6	14
78	High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. Journal of Translational Medicine, 2014, 12, 225.	1.8	77
79	Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion. Biochemical and Biophysical Research Communications, 2014, 448, 424-429.	1.0	52
80	Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncology Letters, 2014, 8, 1739-1744.	0.8	20
81	Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. Journal of Extracellular Vesicles, 2015, 4, 30087.	5.5	1,020
82	Evidence-based support for the use of proton pump inhibitors in cancer therapy. Journal of Translational Medicine, 2015, 13, 368.	1.8	50
83	Inhibition of cell proliferation in gastric cancer cell lines on exposure to rubriflordilactone A. Bangladesh Journal of Pharmacology, 2015, 11, 63.	0.1	0
84	Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget, 2015, 6, 35040-35050.	0.8	48
85	Acid-induced autophagy protects human lung cancer cells from apoptosis by activating ER stress. Experimental Cell Research, 2015, 339, 270-279.	1.2	36
86	TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells. Oncogene, 2015, 34, 5163-5174.	2.6	69
88	Proton channels and exchangers in cancer. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2715-2726.	1.4	158
89	pH―and NIR Lightâ€Responsive Micelles with Hyperthermiaâ€Triggered Tumor Penetration and Cytoplasm Drug Release to Reverse Doxorubicin Resistance in Breast Cancer. Advanced Functional Materials, 2015, 25, 2489-2500.	7.8	218
90	Singlet oxygen treatment of tumor cells triggers extracellular singlet oxygen generation, catalase inactivation and reactivation of intercellular apoptosis-inducing signaling. Redox Biology, 2015, 6, 157-168.	3.9	78
91	Expression and role of V1A subunit of V-ATPases in gastric cancer cells. International Journal of Clinical Oncology, 2015, 20, 725-735.	1.0	32
92	Identification of metals from osteoblastic ST-2 cell supernatants as novel OGR1 agonists. Journal of Receptor and Signal Transduction Research, 2015, 35, 485-492.	1.3	10

#	Article	IF	CITATIONS
93	Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles. Trends in Molecular Medicine, 2015, 21, 595-608.	3.5	133
94	Proton pump inhibitors for the treatment of cancer in companion animals. Journal of Experimental and Clinical Cancer Research, 2015, 34, 93.	3.5	31
95	Facile Synthesis of Core–shell Magnetic Mesoporous Silica Nanoparticles for <scp>pH</scp> â€sensitive Anticancer Drug Delivery. Chemical Biology and Drug Design, 2015, 86, 1548-1553.	1.5	34
96	Increasing the endogenous NO level causes catalase inactivation and reactivation of intercellular apoptosis signaling specifically in tumor cells. Redox Biology, 2015, 6, 353-371.	3.9	72
97	Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resistance Updates, 2015, 23, 69-78.	6.5	202
98	Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. Journal of Experimental and Clinical Cancer Research, 2015, 34, 85.	3.5	131
99	Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Letters, 2015, 356, 697-703.	3.2	81
100	In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer. Frontiers in Oncology, 2016, 6, 164.	1.3	8
101	Effect of Modified Alkaline Supplementation on Syngenic Melanoma Growth in CB57/BL Mice. PLoS ONE, 2016, 11, e0159763.	1.1	31
102	Nitric oxide and pH modulation in gynaecological cancer. Journal of Cellular and Molecular Medicine, 2016, 20, 2223-2230.	1.6	10
103	Spatioâ€Temporal Parameters of Endosomal Signaling in Cancer: Implications for New Treatment Options. Journal of Cellular Biochemistry, 2016, 117, 836-843.	1.2	19
104	Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 119-125.	2.5	54
105	Biodegradable hyperbranched polyether-lipids with in-chain pH-sensitive linkages. Polymer Chemistry, 2016, 7, 6257-6268.	1.9	13
106	Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in Lymphoblastic Leukemia. Cancer Microenvironment, 2016, 9, 119-126.	3.1	23
107	Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis. Cancer Research, 2016, 76, 5201-5208.	0.4	214
108	<i>In Vivo</i> Imaging of Tumor Metabolism and Acidosis by Combining PET and MRI-CEST pH Imaging. Cancer Research, 2016, 76, 6463-6470.	0.4	134
109	Antimicrobial Resistance and Drug Efflux Pumps in Helicobacter. , 2016, , 489-513.		1
110	PLGA nanoparticle encapsulation reduces toxicity while retaining the therapeutic efficacy of EtNBS-PDT in vitro. Scientific Reports, 2016, 6, 33234.	1.6	46

#	Article	IF	CITATIONS
111	ROS homeostasis and metabolism: a critical liaison for cancer therapy. Experimental and Molecular Medicine, 2016, 48, e269-e269.	3.2	211
112	High-Throughput Indirect Quantitation of ¹³ C Enriched Metabolites Using ¹ H NMR. Analytical Chemistry, 2016, 88, 11147-11153.	3.2	13
113	Na ⁺ /H ⁺ exchanger 1, Na ⁺ /Ca ²⁺ exchanger 1 and calmodulin complex regulates interleukin 6-mediated cellular behavior of human hepatocellular carcinoma. Carcinogenesis, 2016, 37, 290-300.	1.3	27
114	Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 269-286.	1.7	95
115	Selective inhibition of tumor cell associated Vacuolarâ€ATPase â€~a2' isoform overcomes cisplatin resistance in ovarian cancer cells. Molecular Oncology, 2016, 10, 789-805.	2.1	27
116	A nonmainstream approach against cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 882-889.	2.5	24
117	Regulation of Ca2+-ATPases,V-ATPases and F-ATPases. , 2016, , .		2
118	Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 538-545.	2.5	47
119	Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering?. Seminars in Cancer Biology, 2017, 43, 111-118.	4.3	48
120	Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. Seminars in Cancer Biology, 2017, 43, 74-89.	4.3	414
121	Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clinical Drug Investigation, 2017, 37, 587-624.	1.1	23
122	The acidic microenvironment as a possible niche of dormant tumor cells. Cellular and Molecular Life Sciences, 2017, 74, 2761-2771.	2.4	86
123	Metacycloprodigiosin induced cell death selectively in β-catenin-mutated tumor cells. Journal of Antibiotics, 2017, 70, 109-112.	1.0	6
124	Regulation of Orai1/STIM1 mediated ICRAC by intracellular pH. Scientific Reports, 2017, 7, 9829.	1.6	14
125	Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemotherapy and Pharmacology, 2017, 80, 925-937.	1.1	51
126	MDR in cancer: Addressing the underlying cellular alterations with the use of nanocarriers. Pharmacological Research, 2017, 126, 2-30.	3.1	49
127	Hypoxia-induced mobilization of NHE6 to the plasma membrane triggers endosome hyperacidification and chemoresistance. Nature Communications, 2017, 8, 15884.	5.8	54
128	Smart pH-sensitive nanoassemblies with cleavable PEGylation for tumor targeted drug delivery. Scientific Reports, 2017, 7, 3383.	1.6	35

#	Article	IF	CITATIONS
129	New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. European Journal of Medicinal Chemistry, 2017, 127, 691-702.	2.6	22
130	Mathematical Models for Acid-Mediated Tumor Invasion: From Deterministic to Stochastic Approaches. Lecture Notes in Computational Science and Engineering, 2017, , 45-71.	0.1	1
131	Multiscale Models in Mechano and Tumor Biology. Lecture Notes in Computational Science and Engineering, 2017, , .	0.1	3
132	The Vacuolar ATPase – A Nano-scale Motor That Drives Cell Biology. Sub-Cellular Biochemistry, 2018, 87, 409-459.	1.0	21
133	Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin. Biochemical and Biophysical Research Communications, 2018, 495, 2004-2009.	1.0	9
134	p53 and glucose metabolism: an orchestra to be directed in cancer therapy. Pharmacological Research, 2018, 131, 75-86.	3.1	83
135	SAHA and cisplatin sensitize gastric cancer cells to doxorubicin by induction of DNA damage, apoptosis and perturbation of AMPK-mTOR signalling. Experimental Cell Research, 2018, 370, 283-291.	1.2	18
136	Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials, 2018, 182, 114-126.	5.7	44
137	Effects of taxol resistance gene 1 on the cisplatin response in gastric cancer. Oncology Letters, 2018, 15, 8287-8294.	0.8	4
138	Na+,HCO3â^' cotransporter NBCn1 accelerates breast carcinogenesis. Cancer and Metastasis Reviews, 2019, 38, 165-178.	2.7	30
139	Live cell imaging of signaling and metabolic activities. , 2019, 202, 98-119.		41
140	Therapy resistance mediated by exosomes. Molecular Cancer, 2019, 18, 58.	7.9	133
141	Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Molecular Cancer, 2019, 18, 69.	7.9	78
142	Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway. Journal of Oncology, 2019, 2019, 1-15.	0.6	28
143	Cell-in-Cell Phenomenon and Its Relationship With Tumor Microenvironment and Tumor Progression: A Review. Frontiers in Cell and Developmental Biology, 2019, 7, 311.	1.8	34
144	An Adaptable Nanoplatform for Integrating Anatomic and Functional Magnetic Resonance Imaging under a 3.0 T Magnetic Field. Advanced Functional Materials, 2019, 29, 1803832.	7.8	14
145	pH-responsive controlled release of mesoporous silica nanoparticles capped with Schiff base copolymer gatekeepers: Experiment and molecular dynamics simulation. Colloids and Surfaces B: Biointerfaces, 2019, 176, 394-403.	2.5	46
146	Fabricating mono-dispersed Fe3O4-SiO2 core-shell particles with help of triboelectrification. Advanced Powder Technology, 2020, 31, 332-338.	2.0	1

#	Article	IF	CITATIONS
147	UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer. Biochemical Pharmacology, 2020, 172, 113745.	2.0	32
148	Targeting Tumor Microenvironment by Small-Molecule Inhibitors. Translational Oncology, 2020, 13, 57-69.	1.7	82
149	Biomedical applications of cerium oxide nanoparticles: a potent redox modulator and drug delivery agent. , 2020, , 283-301.		5
150	Noninvasive Detection of Extracellular pH in Human Benign and Malignant Liver Tumors Using CEST MRI. Frontiers in Oncology, 2020, 10, 578985.	1.3	29
151	Imidazolium-based ionic liquid functionalized mesoporous silica nanoparticles as a promising nano-carrier: response surface strategy to investigate and optimize loading and release process for Lapatinib delivery. Pharmaceutical Development and Technology, 2020, 25, 1150-1161.	1.1	14
152	Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells. Cell Communication and Signaling, 2020, 18, 167.	2.7	37
153	The Ph paradigm in cancer. European Journal of Clinical Nutrition, 2020, 74, 14-19.	1.3	15
154	Advances in the discovery of exosome inhibitors in cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1322-1330.	2.5	74
155	Dual miRNases for Triple Incision of miRNA Target: Design Concept and Catalytic Performance. Molecules, 2020, 25, 2459.	1.7	8
156	Non-invasive Investigation of Tumor Metabolism and Acidosis by MRI-CEST Imaging. Frontiers in Oncology, 2020, 10, 161.	1.3	39
157	Lactate in Sarcoma Microenvironment: Much More than just a Waste Product. Cells, 2020, 9, 510.	1.8	24
158	The pH-centered paradigm in cancer. , 2020, , 53-97.		2
159	Nanomedicine and chemotherapeutics drug delivery: challenges and opportunities. Journal of Drug Targeting, 2021, 29, 185-198.	2.1	16
160	Proton pump inhibitors and other pH-buffering agents. , 2021, , 47-62.		0
161	Insights into the Effects of Dietary Omega-6/Omega-3 Polyunsaturated Fatty Acid (PUFA) Ratio on Oxidative Metabolic Pathways of Oncological Bone Disease and Global Health. Current Medicinal Chemistry, 2021, 28, 1672-1682.	1.2	5
162	Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo. Frontiers in Cell and Developmental Biology, 2021, 9, 655559.	1.8	8
163	Clinical significance of P‑class pumps in cancer (Review). Oncology Letters, 2021, 22, 658.	0.8	8
164	Esomeprazole enhances the effect of ionizing radiation to improve tumor control. Oncotarget, 2021, 12, 1339-1353.	0.8	10

ARTICLE IF CITATIONS # Effect of Exogenous pH on Cell Growth of Breast Cancer Cells. International Journal of Molecular 165 1.8 35 Sciences, 2021, 22, 9910. Old drug, new trick: proton pump inhibitors find new purpose in cancer care. Oncotarget, 2021, 12, 0.8 1861-1862. 167 pH and electrolytes metabolism in prostate cancer., 2021, , 295-318. 0 Contribution of pH Alterations to the Tumor Microenvironment., 2015, , 173-196. Extracellular Glucose Increases the Coupling Capacity of the Yeast V H+-ATPase and the Resistance of 169 1.1 5 Its H+ Transport Activity to Nitrate Inhibition. PLoS ONE, 2012, 7, e49580. Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin. PLoS ONE, 2014, 9, e88193. 171 1.1 Cariporide Enhances the DNA Damage and Apoptosis in Acid-tolerable Malignant Mesothelioma H-2452 172 1.0 6 Cells. Molecules and Cells, 2017, 40, 567-576. Anti-tumor Effect of Quercetin Loaded Chitosan Nanoparticles on Induced Colon Cancer in Wistar 0.6 Rats. Advanced Pharmaceutical Bulletin, 2019, 9, 409-415. Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and 174 0.8 12 reverse transcriptase. Oncotarget, 2017, 8, 4147-4155. Transmembrane voltage potential of somatic cells controls oncogene-mediated tumorigenesis at 0.8 long-range. Oncotarget, 2014, 5, 3287-3306. Vacuolar ATPase â€~a2' isoform exhibits distinct cell surface accumulation and modulates matrix 176 0.8 60 metalloproteinase activity in ovarian cancer. Oncotarget, 2015, 6, 3797-3810. Targeting Notch to overcome radiation resistance. Oncotarget, 2016, 7, 7610-7628. 0.8 50 Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer. World 178 1.4 22 Journal of Gastroenterology, 2017, 23, 2575. A nonlocal sample dependence SDE-PDE system modeling proton dynamics in a tumor. Discrete and Continuous Dynamical Systems - Series B, 2016, 21, 2233-2254. 179 Repeated Administration of Inhibitors for Ion Pumps Reduce Markedly Tumor Growth in Vivo. 180 0.4 8 Medicinski Arhiv = Medical Archives = Archives De Médecine, 2014, 68, 76. Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes. BioImpacts, 2012, 2, 127-43. Tumor microenvironment and nanotherapeutics: intruding the tumor fort. Biomaterials Science, 2021, 182 2.6 30 9,7667-7704. Osmotic and Ionic Regulation in Insects., 2008, , 231-278.

#	Article	IF	CITATIONS
184	How to Overcome Cisplatin Resistance Through Proton Pump Inhibitors. , 2009, , 109-114.		1
185	Cancer in Context: Importance of the Tumor Microenvironment. , 2010, , 43-63.		0
186	V-ATPase Inhibitors in Cancer Treatment and Their Implication in Multidrug Resistance in Oral Squamous Cell Carcinoma. , 0, , .		0
187	Vacuolar H(+)-ATPase in Cancer Cells: Structure and Function. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	Ο
188	The a2 Isoform of Vacuolar ATPase and Cancer-Related Inflammation. , 2014, , 375-392.		0
189	V-ATPases in Oral Squamous Cell Carcinoma Mario Pe´rez-Saya´ns Garcı´a and Abel Garcı´a Garcı´a. , 2 , 393-412.	2014,	0
190	Effect of nonsteroidal ant-inflammatory drugs on carcinogenesis. Onkologiya Zhurnal Imeni P A Gertsena, 2015, 4, 72.	0.0	0
192	V-ATPases and Their Implication in Oral Cancer. , 2016, , 393-405.		0
194	Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1379-1389.	0.4	2
195	Lactic Acidosis Interferes With Toxicity of Perifosine to Colorectal Cancer Spheroids: Multimodal Imaging Analysis. Frontiers in Oncology, 2020, 10, 581365.	1.3	8
196	Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes. American Journal of Cancer Research, 2017, 7, 1913-1925.	1.4	15
197	Proton pump inhibitors and colorectal cancer: A systematic review. World Journal of Gastroenterology, 2021, 27, 7716-7733.	1.4	4
198	Low expression of bestrophin-2 is associated with poor prognosis in colon cancer. Gene, 2022, 813, 146117.	1.0	1
199	Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches. Cancers, 2021, 13, 6135.	1.7	30
200	Physical & Chemical Microwave Ablation (MWA) Enabled by Nonionic MWA Nanosensitizers Repress Incomplete MWA-Arised Liver Tumor Recurrence. ACS Nano, 2022, 16, 5704-5718.	7.3	27
213	Proton Pump Inhibitors Enhance the Antitumor Effect of Chemotherapy for Esophageal Squamous Cell Carcinoma. Cancers, 2022, 14, 2395.	1.7	5
214	Dual-Mode Tumor Imaging Using Probes That Are Responsive to Hypoxia-Induced Pathological Conditions. Biosensors, 2022, 12, 478.	2.3	10
215	Pump proton inhibitors display antiâ€ŧumour potential in glioma. Cell Proliferation, 0, ,	2.4	0

#	Article	IF	CITATIONS
216	Emerging nanomedicines strategies focused on tumor microenvironment against cancer recurrence and metastasis. Chemical Engineering Journal, 2023, 452, 139506.	6.6	13
217	Lactate metabolism in human health and disease. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	196
218	In Vivo MRI-CEST Tumor pH Imaging Detects Resistance to Proton Pump Inhibitors in Human Prostate Cancer Murine Models. Cancers, 2022, 14, 4916.	1.7	7
219	Anticancer activity of nonpolar Pt(CH3)2l2{bipy} is found to be superior among four similar organoplatinum(IV) complexes. Journal of Molecular Structure, 2023, 1274, 134551.	1.8	0
220	Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	35
221	Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer. Experimental and Molecular Medicine, 2022, 54, 1833-1843.	3.2	17
222	Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties. Pharmaceutics, 2022, 14, 2708.	2.0	1
223	Hypoxia, acidification and oxidative stress in cells cultured at large distances from an oxygen source. Scientific Reports, 2022, 12, .	1.6	8
224	Lactate, histone lactylation and cancer hallmarks. Expert Reviews in Molecular Medicine, 2023, 25, .	1.6	12
225	The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis. Cancers, 2023, 15, 284.	1.7	7
226	Gallbladder Cancer: Current Treatment Options and Therapeutics. , 2023, , 3-30.		0
227	Warburg Effect Revisited: Embodiment of Classical Biochemistry and Organic Chemistry. Current State and Prospects. Biochemistry (Moscow), 2023, 88, S1-S20.	0.7	3
228	A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment. Functional and Integrative Genomics, 2023, 23, .	1.4	10
229	How pH deregulation favors the hallmarks of cancer. , 2023, , 101-121.		Ο